Browse studies

Find your next paid study

6 recruiting studies matching your filters

Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy in Participants With Advanced Malignancies

Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.

Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)

Estimated

~$10 – $8,750

Duke Street Bio LtdNCT06458712

Phase 1

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), phar…

Advanced Solid TumorMetastatic Solid TumorProstate Cancer+4 more

Estimated

~$10 – $8,750

MOMA TherapeuticsNCT06545942

Phase 1

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies

ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study ha…

Advanced Malignant NeoplasmBreast CancerOvarian Cancer+3 more

Estimated

~$10 – $8,750

AtlasMedx, IncorporatedNCT04503265

Phase 2

A Phase 2 Trial of Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

The purpose of this study is to determine the objective response rate (ORR) to lorigerlimab in patients with refractory pancreatic ductal adenocarcinoma (PDAC)…

Pancreatic AdenocarcinomaHomologous Recombination Deficiency

Estimated

~$10 – $7,500

Peter Hosein, MDNCT07565155

Phase 2

Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma

In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers w…

MesotheliomaHomologous Recombination Deficiency

Estimated

~$10 – $6,250

University of ChicagoNCT04515836

Phase 1

A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a d…

Advanced Solid TumorHomologous Recombination DeficiencyHRR Deficiency

Estimated

~$10 – $8,750

Eisbach Bio GmbHNCT06525298